Restricted accessResearch articleFirst published online 2012-01
Cooperative Enhancement of Radiosensitivity After Combined Treatment of 17-(Allylamino)-17-Demethoxygeldanamycin and Celecoxib in Human Lung and Colon Cancer Cell Lines
We investigated whether the combined treatment of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of heat-shock protein 90 (hsp90), and celecoxib, an inhibitor of cyclooxygenase-2, can cooperatively enhance the radiosensitivity of various human cancer cells. Combined treatment with 17-AAG and celecoxib, at clinically relevant concentrations, cooperatively induced radiosensitization in all tested cancer cells, but not in normal cells. Cooperative radiosensitization by the drug combination was also shown in a human tumor xenograft system. We found that ataxia-telangiectasia and rad3-related (ATR) and ataxia-telangiectasia mutated (ATM) are novel client proteins of hsp90. Combined treatment with 17-AAG and celecoxib cooperatively induced downregulation of ATR and ATM. In conclusion, combined treatment with 17-AAG and celecoxib at clinically relevant concentrations may significantly enhance the therapeutic efficacy of ionizing radiation.
Get full access to this article
View all access options for this article.
References
1.
BerenbaumM.C.1978. A method for testing for synergy with any number of agents. J Infect Dis, 137:122–130.
2.
ChistiakovD.A., VoronovaN.V., ChistiakovP.A.2008. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol, 47:809–824.
3.
ChouT.C.2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 58:621–681.
4.
DaviesN.M., McLachlanA.J., DayR.O., WilliamsK.M.2000. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet, 38:225–242.
5.
DittmannK.H., MayerC., OhneseitP.A., RajuU., AndratschkeN.H., MilasL., RodemannH.P.2008. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys, 70:203–212.
6.
EnmonR., YangW.H., BallangrudA.M., SolitD.B., HellerG., RosenN., ScherH.I., SgourosG.2003. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res, 63:8393–8399.
7.
FracassoP.M.et al.2011. A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol, 67:1225–1237.
8.
GrecoW.R., BravoG., ParsonsJ.C.1995. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev, 47:331–385.
9.
JunH.J., KimY.M., ParkS.Y., ParkJ.S., LeeE.J., ChoiS.A., PyoH.2009. Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor, Celecoxib. Int J Radiat Oncol Biol Phys, 75:225–234.
10.
KimY.M., LeeE.J., ParkS.Y., ChoK.H., KimJ.Y., PyoH.2009. Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation. Mol Cancer Res, 7:1158–1168.
11.
KobayashiS., NantzR., KitamuraT., HigashikuboR., HorikoshiN.2005. Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation. Oncogene, 24:3011–3019.
12.
McClellanA.J., XiaY., DeutschbauerA.M., DavisR.W., GersteinM., FrydmanJ.2007. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell, 131:121–135.
13.
ModiS.et al.2007. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol, 25:5410–5417.
14.
NeckersL.2007. Heat shock protein 90: the cancer chaperone. J Biosci, 32:517–530.
NomuraM., NomuraN., YamashitaJ.2005. Geldanamycin-induced degradation of Chk1 is mediated by proteasome. Biochem Biophys Res Commun, 335:900–905.
17.
OnK.F., ChenY., MaH.T., ChowJ.P.H., PoonR.Y.C.2011. Determinants of mitotic catastrophe upon abrogation of the G2 DNA damage checkpoint by UCN-01. Mol Cancer Ther, 10:784–794.
18.
ParkJ.S., JunH.J., ChoM.J., ChoK.H., LeeJ.S., ZoJ.I., PyoH.2006. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clin Cancer Res, 12:4989–4999.
19.
PetersonJ.J., NovickS.J.2007. Nonlinear blending: a useful general concept for the assessment of combination drug synergy. J Recept Signal Transduct Res, 27:125–146.
20.
PowersM.V., ClarkeP.A., WorkmanP.2008. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell, 14:250–262.
21.
PowersM.V., WorkmanP.2006. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer, 13,Suppl 1:S125–S135.
22.
PowersM.V., WorkmanP.2007. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett, 581:3758–3769.
23.
PriseK.-M., O'SullivanJ.-M.2009. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer, 9:351–360.
24.
PyoH., ChoyH., AmorinoG.P., KimJ., CaoQ., HerculesS.K., DuBoisR.N.2001. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res, 7:2998–3005.
25.
SauvageotC.M.et al.2009. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol, 11:109–121.
26.
ShinY.K., ParkJ.S., KimH.S., JunH.J., KimG.E., SuhC.O., YunY.S., PyoH.2005. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res, 65:9501–9509.
27.
StravopodisD.J., MargaritisL.H., VoutsinasG.E.2007. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem, 14:3122–3138.
28.
SteelG.G., PeckhamM.J.1979. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys, 5:85–91.
29.
TseA.N., CarvajalR., SchwartzG.K.2007. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res, 13:1955–1960.
30.
TseA.N., SheikhT.N., AlanH., ChouT.C., SchwartzG.K.2009. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol, 75:124–133.
31.
TsutsumiS., ScrogginsB., KogaF., LeeM.J., TrepelJ., FeltsS., CarrerasC., NeckersL.2008. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene, 27:2478–2487.
32.
YanoA., TsutsumiS., SogaS., LeeM.J., TrepelJ., OsadaH., NeckersL.2008. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A, 105:15541–15546.
33.
ZhaoR.et al.2005. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell, 120:715–727.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
